ViewReleaseInStandardHtml

ExpreS2ion Biotech Holding AB:  Last day of trading in BTA

In February 2018, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) conducted a rights issue of shares in which the public also were given the opportunity to subscribe for shares. Through the rights issue, 2,400,403 shares were issued. Last day of trading in BTAs (paid subscription share) is March 15th, 2018 and stop date is March 19th, 2018. 

2,400,403 shares have been registered at the Swedish Companies Registration Office and are estimated to be distributed to each VP account/depot on March 21st, 2018. After the registration at the Swedish Companies Registration Office, the total number of shares in ExpreS2ion is 12,002,015 shares. The share capital after the registration is SEK 1,333,557.222223.

Financial advisor

Sedermera Fondkommission is the financial advisor to ExpreS2ion in connection with the rights issue.

 

Certified Advisor 

Sedermera Fondkommission is appointed as Certified Advisor for ExpreS2ion.

For further information about ExpreS2ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion’s unique proprietary platform technology, ExpreS2, is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS2ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.